Volastra Therapeutics

Focus: Volastra Therapeutics is an oncology-focused biotech company developing therapies for metastatic cancers, currently in early-stage clinical development.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Volastra Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Volastra Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

AMG 650

Advanced Solid Tumors

Phase 1

Sovilnesib

High Grade Serous Adenocarcinoma of Ovary

Phase 1

Clinical Trials (1)

Help build intelligence for Volastra Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage oncology pipeline with 3 active programs targeting solid tumors and ovarian cancer, offering exposure to drug development from Phase 1/2 stage
Small team structure (5 active job openings) enables broad impact and faster decision-making typical of pre-revenue biotech
Focused specialty in metastatic cancer treatment aligns with high unmet medical need and growing investment area

Watch Out For

No revenue, approved products, or financial data available—indicates pre-clinical or very early commercial stage with execution risk
Minimal published data (0 publications) raises questions about scientific visibility and validation within oncology community
Only 3 total pipeline programs with none in Phase 3 creates long timeline to potential value realization or exit

Generated by Claude from Volastra Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NCT06084416A Study of Sovilnesib in Subjects With Ovarian Cancer

Phase 1

VLS-1488

Advanced Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT05902988A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

2 pipeline

Marketed

Pipeline